Etomidate revisited

Current Opinion in Anaesthesiology

Volumn 11, Issue 4, 1998, Pages 391-398

  Ostwald, Philipp ^a,b   Doenicke, Alfred W ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ETOMIDATE; PROPYLENE GLYCOL;

ADRENAL SUPPRESSION; CARDIOVASCULAR EFFECT; DRUG SAFETY; MYOCLONUS; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW;

EID: 0031845289     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-199808000-00003     Document Type: Review

References (99)

1. Kettler D, Sonntag H, Donath U, Regensburger D, Schenk HD. Haemodynamics, myocardial mechanics, oxygen requirement and oxygenation of the human heart during induction of anaesthesia with etomidate. Anaesthesist 1974; 23:116-121.
2. Doenicke A, Gabanyi D, Lemce H, Schurk BM. Haemodynamics and myocardial function after administration of three short-acting i.v. hypnotics, etomidate, propanidid, methohexital. Anaesthesist 1974; 23:108-115.
3. Gooding JM, Corssen G. Etomidate: an ultrashort-acting nonbarbiturate agent for anesthesia induction. Anesth Analg 1976; 55:286-289.
4. Gooding JM, Corssen G. Effect of etomidate on the cardiovascular system. Anesth Analg 1977; 56:717-719.
5. Criado A, Maseda J, Navarro E, Escarpa A, Avello F. Induction of anaesthesia with etomidate: haemodynamic study of 36 patients. Br J Anaesth 1980; 52:803-806.
6. Hempelmann G, Seitz W, Piepenbrock S. Combination of etomidate and fentanyl. Haemodynamics, inotropic state, myocardial oxygen consumption, and vascular reactions. Anaesthesist 1977; 26:231-238.
7. Mayer M, Doenicke A, Nebauer AE, Hepting L. Propofol and etomidate-Lipuro for induction of general anesthesia. Hemodynamics, vascular compatibility, subjective findings and postoperative nausea. Anaesthesist 1996; 45:1082-1084.
8. McCollum JS, Dundee JW. Comparison of induction characteristics of four intravenous anaesthetic agents. Anaesthesia 1986; 41:995-1000.
9. Haessler R, Madler C, Klasing S, Schwender D, Peter K. Propofol/ fentanyl versus etomidate/fentanyl for the induction of anesthesia in patients with aortic insufficiency and coronary artery disease. J Cardiothorac Vasc Anesth 1992; 6:173-180.
10. Lindeburg T, Spotoft H, Bredgaard SM, Skovsted P. Cardiovascular effects of etomidate used for induction and in combination with fentanyl-pancuronium for maintenance of anaesthesia in patients with valvular heart disease. Acta Anaesthesiol Scand 1982; 26:205-208.
11. Gooding JM, Weng JT, Smith RA, Berninger GT, Kirby RR. Cardiovascular and pulmonary responses following etomidate induction of anesthesia in patients with demonstrated cardiac disease. Anesth Analg 1979; 58:40-41.
12. Colvin MP, Savege TM, Newland PE, Weaver EJ, Waters AF, Brookes JM, Inniss R. Cardiorespiratory changes following induction of anaesthesia with etomidate in patients with cardiac disease. Br J Anaesth 1979; 51:551-556.
13. Gelissen HP, Epema AH, Henning RH, Krijnen HJ, Hennis PJ, Den HA. Inotropic effects of propofol, thiopental, midazolam, etomidate, and ketamine on isolated human atrial muscle. Anesthesiology 1996; 84:397-403.
14. Stowe DF, Bosnjak ZJ, Kampine JP. Comparison of etomidate, ketamine, midazolam, propofol, and thiopental on function and metabolism of isolated hearts. Anesth Analg 1992; 74:547-558.
15. Buljubasic N, Marijic J, Berczi V, Supan DF, Kampine JP, Bosnjak ZJ. Differential effects of etomidate, propofol, and midazolam on calcium and potassium channel currents in canine myocardial cells. Anesthesiology 1996; 85:1092-1099.
16. Zhou W, Fontenot HJ, Liu S, Kennedy RH. Modulation of cardiac calcium channels by propofol. Anesthesiology 1997; 86:670-675.
17. Mazerolles M, Senard JM, Verwaerde P, Tran MA, Montastruc JL, Virenque C, Montastruc P. Effects of pentobarbital and etomidate on plasma catecholamine levels and spectral analysis of blood pressure and heart rate in dogs. Fundam Clin Pharmacol 1996; 10:298-303.
18. Ebert TJ, Muzi M, Berens R, Goff D, Kampine JP. Sympathetic responses to induction of anesthesia in humans with propofol or etomidate. Anesthesiology 1992; 76:725-733.
19. Kugler J, Doenicke A, Laub M. The EEG after etomidate. Anaesthesiol Wiederbelebung 1977; 106:31-48.
20. Holdcroft A, Morgan M, Whitwam JG, Lumley J. Effect of dose and premedication on induction complications with etomidate. Br J Anaesth 1976; 48:199-205.
21. Carlos R, Innerarity S. Effect of premedication on etomidate anaesthesia. Br J Anaesth 1979; 51:1159-1162.
22. Modica PA, Tempelhoff R, White PF. Pro- and anticonvulsant effects of anesthetics (Part II) [see comments]. Anesth Analg 1990; 70:433-444.
23. Sloan TB, Ronai AK, Toleikis JR, Koht A. Improvement of intraoperative somatosensory evoked potentials by etomidate. Anesth Analg 1998; 67:582-585.
24. McPherson RW, Sell B, Traystman RJ. Effects of thiopental, fentanyl, and etomidate on upper extremity somatosensory evoked potentials in humans. Anesthesiology 1986; 65:584-589.
25. Doenicke A, Kugler J, Penzel G, Laub M, Kalmar L, Killian l, Bezecny H. Cerebral function under etomidate, a new nonbarbiturate i.v. hypnotic (author's translation). Anesthesist 1973; 22:357-366.
26. Reddy RV, Moorthy SS, Dierdorf SF, Deitch RD Jr, Link L. Excitatory effects and electroencephalographic correlation of etomidate, thiopental, methohexital, and propofol. Anesth Analg 1993; 77:1008-1011.
27. Doenicke A, Roizen MF, Kugler J, Kroll H, Foss J. Does 'priming' decrease the incidence of myoclonus with etomidate? [abstract]. Anesthesiology 1997; 87:A302.
28. Ghoneim MM, Yamada T. Etomidate: a clinical and electroencephalographic comparison with thiopental. Anesth Analg 1977; 56:479-485.
29. Krieger W, Copperman J, Laxer KD. Seizures with etomidate anesthesia [letter]. Anesth Analg 1985; 64:1226-1227.
30. Lowson S, Gent JP, Goodchild CS. Convulsive thresholds in mice during the recovery phase from anaesthesia induced by propofol, thiopentone, methohexitone and etomidate. Br J Pharmacol 1991; 102:879-882.
31. Hoffmann P, Schockenhoff B. Etomidate as an anticonvulsive agent. Anaesthesist 1984; 33:142-144.
32. Yeoman P, Hutchinson A, Byrne A, Smith J, Durham S. Etomidate infusions for the control of refractory status epilepticus. Intensive Care Med 1989; 15:255-259.
33. Payne TA, Bleck TP. Status epilepticus. Crit Care Clin 1997; 13:17-38.
34. Krieger W, Koerner M. Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia [letter]. Anesth Analg 1987; 66:284-285.
35. Gancher S, Laxer KD, Krieger W. Activation of epileptogenic activity by etomidate. Anesthesiology 1984; 61:616-618.
36. Ebrahim ZY, Deboer GE, Luders H, Hahn JF, Lesser RP. Effect of etomidate on the electroencephalogram of patients with epilepsy. Anesth Analg 1986; 65:1004-1006.
37. Doenicke A, Roizen MF, Kugler J, Kroll H. Is myoclonus after etomidate dose-related? [abstract]. Anesthesiology 1997; 87:A315.
38. Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients [letter]. Lancet 1983; 1:1270.
39. Engelhardt D, Doenicke A, Suttmann H, Kupper FJ, Braun S, Muller OA. Effect of etomidate and thiopental on ACTH and cortisol levels in serum. A prospective controlled comparative study in healthy probands. Anesthesiology 1984; 33:583-587.
40. Fragen RJ, Shanks CA, Molteni A, Avram MJ. Effects of etomidate on hormonal responses to surgical stress. Anesthesiology 1984; 61:652-656.
41. Fry DE, Griffiths H. The inhibition by etomidate of the 11 beta-hydroxylation of cortisol. Clin Endocrinol Oxford 1984; 20:625-629.
42. Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984; 310:1415-1421.
43. Wagner RL, White PF. Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology 1984; 61:647-651.
44. Duthie DJ, Fraser R, Nimmo WS. Effect of induction of anaesthesia with etomidate on corticosteroid synthesis in man. Br J Anaesth 1985; 57:156-159.
45. Allolio B, Dorr H, Stuttmann R, Knorr D, Engelhardt D, Winkelmann W. Effect of a single bolus of etomidate upon eight major corticosteroid hormones and plasma ACTH. Clin Endocrinol Oxford 1985; 22:281-286.
46. DeCoster R, Helmers JH, Noorduin H. Effect of etomidate on cortisol biosynthesis: site of action after induction of anaesthesia. Acta Endocrinol Copenhagen 1985; 110:526-531.
47. Crozier TA, Schlaeger M, Wuttke W, Kettler D. TIVA with etomidatefentanyl versus midazolam-fentanyl. The perioperative stress f coronary surgery overcomes the inhibition of cortisol synthesis caused by etomidate-fentanyl anesthesia. Anaesthesist 1994; 43:605-613.
48. Schraag S, Pawlik M, Mohl U, Bohm BO, Georgieff M. The role of ascorbic acid and xylitol in etomidate-induced adrenocortical suppression in humans. Eur J Anaesthesiol 1996; 13:346-351.
49. Jameson P, Desborough JP, Bryant AE, Hall GM. The effect of cortisol suppression on interleukin-6 and white blood cell responses to surgery. Acta Anaesthesiol Scand 1997; 41:304-308.
50. Doenicke A, Nebauer AE, Hoernecke R, Mayer M, Roizen MF. Osmolalities of propylene glycol-containing drug formulations for parenteral use. Should propylene glycol be used as a solvent? Anesth Analg 1992; 75:431-435.
51. Doenicke A, Roizen MF, Nebauer AE, Kugler A, Hoernecke R, Beger HH. A comparison of two formulations for etomidate, 2-hydroxypropyl-beta-cyclodextrin (HPCD) and propylene glycol. Anesth Analg 1994; 79:933-939.
52. Ruo W, Shay J, Attele A, Doenicke A, Moss J. Propylene glycol damages vascular smooth muscle and endothelium [abstract], Anesthesiology 1992; 77S:A1096.
53. Doenicke A, Hoernecke R, Moss J, Roizen MF. Etomidate in lipid emulsion prevents injection pain and phlebitis [abstract]. Anesth Analg 1997; 84:8475.
54. Zacharias M, Clarke RS, Dundee JW, Johnston SB. Venous sequelae following etomidate. Br J Anaesth 1979; 51:779-783.
55. Zacharias M, Clarke RS, Dundee JW, Johnston SB. Evaluation of three preparations of etomidate. Br J Anaesth 1978; 50:925-929.
56. Sold M, Rothhammer A. Life-threatening anaphylactoid reaction following etomidate. Anaesthesist 1985; 34:208-210.
57. Krumholz W, Muller H, Gerlach H, RUSS W, Hempelmann G. A case of anaphylactoid reaction following administration of etomidate. Anaesthesist 1984; 33:161-162.
58. Levy ML, Aranda M, Zelman V, Giannotta SL. Propylene glycol toxicity following continuous etomidate infusion for the control of refractory cerebral edema. Neurosurgery 1995; 37:363-369.
59. Doenicke A, Roizen MF, Hoernecke R, Ostwald P, Foss J. Haemolysis after etomidate: comparison of propylene glycol and lipid formulations. Br J Anaesth 1997; 79:386-388.
60. Pearl RG, Rice SA. Propylene-glycol-induced pulmonary hypertension in sheep. Pharmacology 1989; 39:383-389.
61. Martin G, Finberg L. Propylene glycol: a potentially toxic vehicle in liquid dosage form. J Pediatr 1970; 77:877-878.
62. Christopher MM, Eckfeldt JH, Eaton JW. Propylene glycol ingestion causes D-lactic acidosis. Lab Invest 1990; 62:114-118.
63. Bedichek E, Kirschbaum B. A case of propylene glycol toxic reaction associated with etomidate infusion. Arch Intern Med 1991; 151:2297-2298.
64. Doenicke A, Kugler A, Vollmann N, Suttmann H, Taeger K. Etomidate using a new solubilizer. Experimental clinical studies on venous tolerance and bioavailability. Anaesthesist 1990; 39:475-480.
65. Suttmann H, Doenicke A, Kugler J, Laub M. A new formulation of etomidate in lipid emulsion-bioavailability and venous provocation. Anaesthesist 1989; 38:421-423.
66. Doenicke A, Hoernecke R, Nebauer AE, O'Connor MF, Lorenz W, Mayer M et al. Lipid emulsion is superior to propylene glycol as a vehicle for etomidate [abstract]. Anesthesiology 1992; 77:A346.
67. Fazackerley EJ, Martin AJ, Tolhurst CC, Watkins J. Anaphylactoid reaction following the use of etomidate. Anaesthesia 1988; 43:953-954.
68. Watkins J. Etomidate: an 'immunologically safe' anaesthetic agent. Anaesthesia 1983; 38 (Suppl):34-38.
69. Laxenaire M-C, Moneret-Vautrin D-A. Allergy and anaesthesia. Aether 1994; 1:14-18.
70. Suresh MS, Nelson TE. Malignant hyperthermia: is etomidate safe? Anesth Analg 1985; 64:420-424.
71. Malignant Hyperthermia Association of The United States. Managing malignant hyperthermia. Rev Mex Anest 1997; 20:156-161.
72. Cheng MA, Theard MA, Tempelhoff R. Intravenous agents and intraoperative neuroprotection. Beyond barbiturates. Crit Care Clin 1997; 13:185-199.
73. Jellish WS, Riche H, Salord F, Ravussin P, Tempelhoff R. Etomidate and thiopental-based anesthetic induction: comparisons between different titrated levels of electrophysiologic cortical depression and response to laryngoscopy. J Clin Anesth 1997; 9:36-41.
74. Davis DW, Mans AM, Biebuyck JF, Hawkins RA. Regional brain glucose utilization in rats during etomidate anesthesia. Anesthesiology 1986; 64:751-757.
75. Milde LN, Milde JH, Michenfelder JD. Cerebral functional, metabolic, and hemodynamic effects of etomidate in dogs. Anesthesiology 1985; 63:371-377.
76. Hoffman WE, Charbel FT, Ausman JI. Cerebral blood flow and metabolic response to etomidate and ischemia. Neural Res 1997; 19:41-44.
77. Watson JC, Drummond JC, Patel PM, Sano T, Akrawi W. An assessment of the cerebral protective effects of etomidate in a model of incomplete forebrain ischemia in the rat. Neurosurgery 1992; 30:540-544.
78. Smith DS, Keykhah MM, O'Neill JJ, Harp JR. The effect of etomidate pretreatment on cerebral high energy metabolites, lactate, and glucose during severe hypoxia in the rat. Anesthesiology 1989; 71:438-443.
79. Milde LN, Milde JH. Preservation of cerebral metabolites by etomidate during incomplete cerebral ischemia in dogs. Anesthesiology 1986; 65:272-277.
80. Drummond JC, Cole DJ, Patel PM, Reynolds LW. Focal cerebral ischemia during anesthesia with etomidate, isoflurane, or thiopental: a comparison of the extent of cerebral injury. Neurosurgery 1995; 37:742-748.
81. Quo J, White JA, Batjer HH. Limited protective effects of etomidate during brainstem ischemia in dogs. J Neurosurg 1995; 82:278-283.
82. Baughman VL, Hoffman WE, Miletich DJ, Albrecht RF. Cerebral metabolic depression and brain protection produced by midazolam and etomidate in the rat. J Neurosurg Anesthesiol 1989; 1:22-28.
83. Edelman GJ, Hoffman WE, Charbel FT. Cerebral hypoxia after etomidate administration and temporary cerebral artery occlusion. Anesth Analg 1997; 85:821-825.
84. Bergen JM, Smith DC. A review of etomidate for rapid sequence intubation in the emergency department. J Emerg Med 1997; 15:221-230.
85. Plewa MC, King R, Johnson D, Adams D, Engoren M. Etomidate use during emergency intubation of trauma patients [letter]. Am J Emerg Med 1997; 15:98-100.
86. Stevens JB, Vescovo MV, Harris KC, Walker SC, Hickey R. Tracheal intubation using alfentanil and no muscle relaxant: is the choice of hypnotic important? Anesth Analg 1997; 84:1222-1226.
87. Franks NP, Lieb WR. Molecular and cellular mechanisms of general anaesthesia. Nature 1994; 367:607-614.
88. Franks NP, Lieb WR. Inhibitory synapses. Anaesthetics set their sites on ion channels. Nature 1997; 389:334-335. This gives an excellent overview about the recent advances on how anaesthetics work in the CNS.
89. Franks NP, Lieb WR. An anesthetic-sensitive superfamily of neurotransmitter-gated ion channels. J Clin Anesth 1996; 8:3-7S.
90. A receptor subtypes, Inf Rev Neurobiol 1995; 38:95-138.
91. A receptor-gated currents in cultured postnatal hippocampal neurons. Neuroscience 1996; 73:69-78.
92. A-receptor.
93. A-receptor.
94. A-receptor.
95. Hill VC, Belelli D, Peters JA, Lambert JJ. Subunit-dependent interaction of the general anaesthetic etomidate with the gamma-aminobutyric acid type A receptor. Br J Pharmacol 1997; 120:749-756.
96. Sanna E, Murgia A, Casula A, Biggio G. Differential subunit dependence of the actions of the general anesthetics alphaxalone and etomidate at gamma-aminobutyric acid type A receptors expressed in Xenopus laevis oocytes. Mol Pharmacol 1997; 51:484-490.
97. A beta-subunit homomeric receptors. Neuroreport 1996; 7:943-947.
98. A receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci 1992; 12:1040-1062.
99. Homanics GE, Delorey TM, Firestone LL, Quinlan JJ, Handforth A, Harrison NL, et al. Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior. Proc Natl Acad Sci U S A 1997; 94:4143-4148.